Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Specific vaccines against autoimmune diseases.

M Sela1

  • 1Department of Immunology, Weizmann Institute of Science, Rehovot, Israel. lisela@weizmann.weizmann.ac.il

Comptes Rendus De L'Academie Des Sciences. Serie III, Sciences De La Vie
|January 26, 2000
PubMed
Summary

Copolymer 1 (Cop 1) effectively treats multiple sclerosis (MS) by modulating T-cell responses. This antigen-specific therapy also shows promise for myasthenia gravis (MG) by targeting autoimmune mechanisms.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

NOX1-induced accumulation of reactive oxygen species in abdominal fat-derived mesenchymal stromal cells impinges on long-term proliferation.

Cell death & disease·2015
Same author

From synthetic antigens to synthetic vaccines.

Immunology today·2014
Same author

[50] Reaction with N-carboxy-α-amino acid anhydrides.

Methods in enzymology·2012
Same author

The relationship between HLA antigens and Bermuda grass hayfever.

Immunogenetics·2011
Same author

Combining epitope-distinct antibodies to HER2: cooperative inhibitory effects on invasive growth.

Oncogene·2010
Same author

A dual altered peptide ligand inhibits myasthenia gravis associated responses by inducing phosphorylated extracellular-regulated kinase 1,2 that upregulates CD4+CD25+Foxp3+ cells.

Scandinavian journal of immunology·2007

Area of Science:

  • Neuroimmunology
  • Autoimmune Diseases
  • Pharmacology

Background:

  • Copolymer 1 (Cop 1, Copaxone) is a synthetic amino acid copolymer with demonstrated efficacy in suppressing experimental allergic encephalomyelitis (EAE).
  • Clinical trials show Cop 1 slows disability progression and reduces relapse rates in patients with exacerbating-remitting multiple sclerosis (MS).
  • The mechanism involves Cop 1 binding to MHC class II molecules, competing with myelin antigens for T-cell activation, and inducing Th2-type suppressor cells.

Purpose of the Study:

  • To investigate the therapeutic potential and mechanism of action of Cop 1 in MS.
  • To explore a similar antigen-specific therapeutic approach for myasthenia gravis (MG).
  • To study T cells specific to myasthenic epitopes of the acetylcholine receptor alpha-subunit in MG.

Main Methods:

Related Experiment Videos

  • In vivo and in vitro studies of Cop 1's mechanism in EAE and MS.
  • Phase II and III clinical trials of Cop 1 in MS patients.
  • Analysis of T cells specific to acetylcholine receptor alpha-subunit epitopes in MG and its animal model (EAMG).

Main Results:

  • Cop 1 demonstrates broad suppressive effects in EAE across different species, disease types, and encephalitogens.
  • Cop 1 is a safe and effective therapeutic approach for MS, reducing disability and relapse rates.
  • Studies highlight the role of T cells specific to myasthenogenic epitopes in MG pathogenesis and immunomodulation.

Conclusions:

  • Cop 1 represents a safe and effective antigen-specific therapy for MS, with a favorable safety profile.
  • The success of Cop 1 in MS supports a novel concept of disease-specific autoimmune drug/vaccine development.
  • Similar antigen-specific strategies targeting T cells are relevant for treating myasthenia gravis.